1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow [18F]NOTA-ABY-030: new trials by email Literature Review of [18F]NOTA-ABY-030 trials Research Report on [18F]NOTA-ABY-030
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma Panitumumab-IRDye800, [18F]NOTA-ABY-030 - HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2026-10-01 | 2026-10-19 |
Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Squamous Cell Carcinoma of Head and Neck (1)
Vanderbilt-Ingram Cancer Center (1)
United States (1)